Posts Tagged ‘heart disease’

Omega 3 pharmaceutical grade fish oil EPA reduces LDL cholesterol levels

Sunday, April 29th, 2012

Omega 3 EPA reduces LDL cholesterol levels –

New clinical study results presented at the American Heart Association Scientific Sessions show that the long-chain omega-3 fatty acid EPA (eicosapentaenoic acid), helped significantly reduce small dense LDL (bad) cholesterol levels.

“This study suggests that supplementation with the omega-3 fatty acid EPA may present unique benefits for cardiovascular health,” said Sujata K. Bhatia, M.D., Ph.D., research associate with DuPont. “EPA was shown to have advantageous effects on several biomarkers, including LDL cholesterol, small dense LDL, and lp-PLA2.”

EPA is a long-chain fatty acid that is found primarily in cold water, fatty fish like sardines anchovies mackerel as well as some omega-3 fatty acid such as TakeOmega3 which has 750 mg EPA per capsule and is the highest grade omega 3 available in UK . A growing body of evidence suggests that EPA is the long-chain omega-3 that supports heart health.

The study, conducted by Cardiovascular Research Associates and sponsored by DuPont, was conducted among 110 healthy individuals comparing the effects of EPA supplements to DHA (docosahexaenoic acid) supplements on cardiovascular health. The participants were placed into four study groups and examined over a six week period. During that time, each group was monitored while taking: EPA 600 mg per day; EPA 1,800 mg per day; DHA 600 mg per day; and an olive oil placebo.

The study found that in the 1,800mg EPA group, there were significant reductions of 7 percent for small dense low density lipoprotein (LDL) cholesterol, and 6 percent for lipoprotein-associated phospholipase A2 (lp-PLA2). lp-PLA2 is an enzyme involved in vascular inflammation.

In contrast, the 600mg DHA group showed a significant increase in total small dense LDL cholesterol in both the fasting and fed state of 14.2 percent and 16.3 percent respectively.

The study results will be featured during the American Heart Association Conference poster session in Chicago

Omacor contains 375mg DHA just two capsules exceeds the 600mg DHA level that shows an increase in LDL C – on a 4 capsule per dose dose that would deliver 1500 mg of DHA which is more than double the dose that showed a 14.2 % and 16.3% increase in small dense LDL

BENEFICIAL EFFECT OF EICOSAPENTAENOIC ACID ON ENDOTHELIAL FUNCTION IN OLD MYOCARDIAL INFARCTION PATIENTS UNDER ADEQUATE STATIN THERAPY

Sunday, April 29th, 2012

BENEFICIAL EFFECT OF EICOSAPENTAENOIC ACID ON ENDOTHELIAL FUNCTION IN OLD MYOCARDIAL INFARCTION PATIENTS UNDER ADEQUATE STATIN THERAPY

Kentaro Toyama, Osamu Sasaki, Toshihiko Nishioka and Hiroyuki Ito
Department of cardiology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

J Am Coll Cardiol, 2012; 59:1773, doi:10.1016/S0735-1097(12)61774-4
© 2012 by the American College of Cardiology Foundation

Eicosapentaenoic acid (EPA) is reported to augment endothelial function and improve clinical outcomes in patients with coronary artery disease. However, it is unclear whether the effect of EPA is preserved even in patients under adequate statin therapy as secondary prevention. We hypothesized that EPA could improve endothelial function in old myocardial patients (OMI) with adequate lipid-lowering treatment using statin.
Fifty-five OMI patients under statin treatment with serum LDL cholesterol levels less than 100 mg/dl were randomly assigned to receive either 1800 mg of EPA daily with statin (EPA group, n=29) or statin alone (non-EPA group, n=26). Lipid profiles and flow-mediated dilation (FMD) were assessed just before and 6 months after the randomization in both groups.

EPA group presented significant increase in plasma concentrations of EPA (p<0.001). In EPA group, LDL-cholesterol and trygliceride levels significantly decreased (p<0.05), whereas no significant change was seen in non-EPA group. FMD, which is the primary end point of this study, showed significant improvement in EPA group (2.41±1.46% to 3.18±1.82%, p=0.001), while no significant change was seen in non-EPA group (2.51±1.48% to 2.25±1.42%, p=NS). Furthermore, FMD defined as post FMD - pre FMD significantly increased in EPA group (0.77±1.17 vs –0.25±1.59, p=0.009).

EPA further improved endothelial function in old myocardial infarction patients under adequate statin therapy.

Omega-3 fish oil essential fatty acids Significantly Improves The Endothelial Function

Thursday, April 5th, 2012

Omega-3 fish oil essential fatty acids Significantly Improves The Endothelial Function

Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: A meta-analysis of randomized controlled trials. Atherosclerosis. 2012 Apr;221(2):536-43.

OBJECTIVE:
Inverse association was reported between omega-3 fatty acids (FAs) supplementation and the risk of cardiovascular disease. Identifying the effect of omega-3 FAs on endothelial function may contribute to explain the association. We conducted a meta-analysis to assess the effect of omega-3 FAs supplementation on endothelial function, as measured by flow-mediated dilation (FMD) and endothelium-independent vasodilation (EIV).

METHODS:
Randomized placebo-controlled trials (RCTs) were identified from the databases of PubMed, EMBASE and Cochrane library by two investigators and the pooled effects were measured by weighted mean difference (WMD), together with 95% confidence intervals (CIs). Subgroup and meta-regression analyses were used to explore the source of between-study heterogeneity.

RESULTS:
Totally 16 eligible studies involving 901 participants were finally included in meta-analysis. Compared with placebo, omega-3 FAs supplementation significantly increased FMD by 2.30% (95% CI: 0.89-3.72%, P=0.001), at a dose ranging from 0.45 to 4.5g/d over a median of 56days. Subgroup analyses suggested that the effect of omega-3 FAs on FMD might be modified by the health status of the participants or the dose of supplementation. Sensitivity analyses indicated that the protective effect of omega-3 on endothelial function was robust. No significant change in EIV was observed after omega-3 FAs supplementation (WMD: 0.57%; 95% CI: -0.88 to 2.01%; P=0.442).
he loss of proper endothelial function, is a hallmark for vascular diseases, and is often regarded as a key early event in the development of atherosclerosis. Impaired endothelial function, causing hypertension and thrombosis, is often seen in patients with coronary artery disease, diabetes mellitus, hypertension, hypercholesterolemia, as well as in smokers.
CONCLUSION:
Supplementation of omega-3 fatty acids significantly improves the endothelial function without affecting endothelium-independent dilation

Omega 3 fish oil EPA Slows Progress of Atherosclerosis in Diabetic Patients

Tuesday, July 12th, 2011

EPA Slows Progress of Atherosclerosis in Diabetic Patients

People with type 2 diabetes are more likely to develop heart disease, circulatory problems and damaged organs than people without the condition. Impaired blood circulation, particularly in the small blood vessels, contributes to damaged eyes, kidneys and feet. Thus, in caring for diabetic patients, doctors pay close attention to blood circulation. To date, there are not many ways of improving the damaged blood vessels that develop in atherosclerosis and type 2 diabetes.

The fatty acids in fish oils, known as long-chain omega-3s, are known to improve blood vessel function in patients with heart disease. They relax the muscles in the blood vessel walls, reduce inflammation and lower blood clotting. These properties make them good candidates for improving blood vessel function in type 2 diabetics. Accordingly, a team of Japanese investigators examined the effect of consuming nearly 2 g/day of EPA, on the thickness of the carotid artery wall in diabetic patients. EPA is one of the major long-chain omega-3 fatty acids in fish oil. This dose is about the equivalent of 2 servings of salmon/day. Study participants consumed the omega-3 supplements for 2 years. Patients who were given standard medical treatment, but no supplements, were used for comparison.

At the end of the study, patients consuming EPA had a significant decrease of 4.7% in the thickness of their carotid wall compared with an increase of 2.4% in patients receiving standard care. Measurements of blood flow also improved in the EPA patients. There was a small increase in glycosylated hemoglobin, a sensitive measure of elevated blood glucose, in the EPA group and a decrease in the control patients. While this outcome was undesirable, such values in individual patients would call for aggressive patient management. This finding indicates that diabetic patients who consume large amounts of fish oil should be regularly monitored by their doctors for blood glucose control. With regular check-ups, diabetic patients can obtain the heart and circulatory system benefits of fish oil without compromising their diabetes status. Overall, this study adds to the growing evidence that long-chain omega-3 fatty acids may slow the progression of atherosclerosis in patients with type 2 diabetes or coronary artery disease.

Omega 3 EPA fish oil benefits helps prevent obesity related diseases such as diabetes and heart disease

Friday, March 25th, 2011

A new study has suggested that a high intake of omega-3 fats found in fish helps prevent obesity-related chronic diseases such as diabetes and heart disease. Fish oil benefits .

The scientists come to the conclusion after studying Yup’ik Eskimos in Alaska, who on average consume 20 times more omega-3 fats from fish than people in the lower 48 states.

Researchers at Fred Hutchinson Cancer Research Center in collaboration conducted the study with the Center for Alaska Native Health Research at the University of Alaska-Fairbanks.

The fats the researchers were interested in measuring were those found in salmon, sardines and other fatty fish: docosahexaenoic acid, or DHA, and eicosapentaenoic acid, or EPA.

Researchers analyzed data from a community-based study of 330 people living in the Yukon Kuskokwim Delta region of southwest Alaska, 70 percent of whom were overweight or obese.

As expected, the researchers found that in participants with low blood levels of DHA and EPA, obesity strongly increased both blood triglycerides (a blood lipid abnormality) and C-reactive protein, or CRP (a measure of overall body inflammation).

Elevated levels of triglycerides and CRP increase the risk of heart disease and, possibly, diabetes.

“These results mimic those found in populations living in the Lower 48 who have similarly low blood levels of EPA and DHA,” said senior author Alan Kristal.

“However, the new finding was that obesity did not increase these risk factors among study participants with high blood levels of omega-3 fats, he said.

Lead author Zeina Makhoul said, “Interestingly, we found that obese persons with high blood levels of omega-3 fats had triglyceride and CRP concentrations that did not differ from those of normal-weight persons.

“It appeared that high intakes of omega-3-rich seafood protected Yup’ik Eskios from some of the harmful effects of obesity,” Makhoul added.

The study was published online March 23 in the European Journal of Clinical Nutrition. (ANI)

Great Britain Flag
Made in the UK - Take Omega 3 Suspendisse lacinia ultricies justo, at ultricies nisi tempus ac. Cras sed vehicula metus. Phasellus...